دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
In the Literature
Stan Deresinski
doi : 10.1093/cid/ciac838
Clinical Infectious Diseases, Volume 76, Issue 1, 1 January 2023, Pages i–ii
Principles for Ending Human Immunodeficiency Virus as an Epidemic in the United States: A Policy Paper of the Infectious Diseases Society of America and the HIV Medical Association
Anna K Person, Wendy S Armstrong, Tyler Evans, John J W Fangman, Robert H Goldstein, Marwan Haddad, Mamta K Jain, Susana Keeshin, Hansel E Tookes, Andrea L Weddle, Judith Feinberg
doi : 10.1093/cid/ciac626
Clinical Infectious Diseases, Volume 76, Issue 1, 1 January 2023, Pages 1–9
While we have the tools to achieve this goal, the persistent barriers to healthcare services experienced by too many individuals will need to be addressed to make significant progress and improve the health and quality of life of all people with human immunodeficiency virus (HIV).
Optimal Timing of Antiretroviral Therapy Initiation in Children and Adolescents With Human Immunodeficiency Virus-Associated Pulmonary Tuberculosis
Alexander Kay, Jose Mendez-Reyes, Tara Devezin, Meenakshi Bakaya, Teresa Steffy, Sandile Dlamini, Amos Msekandiana, Tara Ness, Jason Bacha, Pauline Amuge, Mogomotsi Matshaba, Moses Chodota, Phoebe Nyasulu, Lineo Thahane, Lumumbwa Mwita, Adeodata Kekitiinwa, Andrew DiNardo, Bhekumusa Lukhele, H Lester Kirchner, Anna Mandalakas
doi : 10.1093/cid/ciac765
Clinical Infectious Diseases, Volume 76, Issue 1, 1 January 2023, Pages 10–17
There is insufficient evidence in children and adolescents with human immunodeficiency virus (CAHIV) to guide the timing of antiretroviral treatment (ART) initiation after starting treatment for pulmonary tuberculosis (pTB).
Comparative Effectiveness of BNT162b2 and mRNA-1273 Booster Dose After BNT162b2 Primary Vaccination Against the Omicron Variants: A Retrospective Cohort Study Using Large-Scale Population-Based Registries in Japan
Sachiko Ono, Nobuaki Michihata, Hayato Yamana, Kohei Uemura, Yosuke Ono, Taisuke Jo, Hideo Yasunaga
doi : 10.1093/cid/ciac763
Clinical Infectious Diseases, Volume 76, Issue 1, 1 January 2023, Pages 18–24
Direct comparative effectiveness of booster doses of BNT162b2 and mRNA-1273 after BNT162b2 primary vaccination is unknown.
Virologic Failure Following Low-level Viremia and Viral Blips During Antiretroviral Therapy: Results From a European Multicenter Cohort
Olof Elvstam, Kasper Malmborn, Sixten Elén, Gaetano Marrone, Federico GarcÃa, Maurizio Zazzi, Anders Sönnerborg, Michael Böhm, Carole Seguin-Devaux, Per Björkman
doi : 10.1093/cid/ciac762
Clinical Infectious Diseases, Volume 76, Issue 1, 1 January 2023, Pages 25–31
It is unclear whether low-level viremia (LLV), defined as repeatedly detectable viral load (VL) of <200 copies/mL, and/or transient viremic episodes (blips) during antiretroviral therapy (ART), predict future virologic failure. We investigated the association between LLV, blips, and virologic failure (VF) in a multicenter European cohort.
Qualitative Subgenomic RNA to Monitor the Response to Remdesivir in Hospitalized Patients With Coronavirus Disease 2019: Impact on the Length of Hospital Stay and Mortality
Rodrigo Alonso-Navarro, Genoveva Cuesta, Marta Santos, Celia Cardozo, Verónica Rico, Nicole Garcia-Pouton, Montse Tuset, Marta Bodro, Laura Morata, Pedro Puerta-Alcalde, Sabina Herrera, Dafne Soria, Marta Aldea, Josep Mensa, José Antonio MartÃnez, Ana del Rio, Jordi Vila, Felipe Garcia, Carolina Garcia-Vidal, M Angeles Marcos, Alex Soriano
doi : 10.1093/cid/ciac760
Clinical Infectious Diseases, Volume 76, Issue 1, 1 January 2023, Pages 32–38
There is no reliable microbiological marker to guide the indication and the response to antiviral treatment in patients with coronavirus disease 2019 (COVID-19). We aimed to evaluate the dynamics of subgenomic RNA (sgRNA) in patients with COVID-19 before and after receiving treatment with remdesivir.
Same-Day Antiretroviral Therapy Initiation as a Predictor of Loss to Follow-up and Viral Suppression Among People With Human Immunodeficiency Virus in Sub-Saharan Africa
Jonathan Ross, Ellen Brazier, Geoffrey Fatti, Antoine Jaquet, Aristophane Tanon, Andreas D Haas, Lameck Diero, Barbara Castelnuovo, Constantin T Yiannoutsos, Denis Nash, Kathryn M Anastos, Marcel Yotebieng
doi : 10.1093/cid/ciac759
Clinical Infectious Diseases, Volume 76, Issue 1, 1 January 2023, Pages 39–47
Treat-All guidelines recommend initiation of antiretroviral therapy (ART) for all people with HIV (PWH) on the day of diagnosis when possible, yet uncertainty exists about the impact of same-day ART initiation on subsequent care engagement.
Polygenic Risk Scores for Prediction of Subclinical Coronary Artery Disease in Persons With Human Immunodeficiency Virus (HIV): The Swiss HIV Cohort Study
Isabella C Schoepf, Christian W Thorball, Helen Kovari, Bruno Ledergerber, Ronny R Buechel, Alexandra Calmy, Rainer Weber, Philipp A Kaufmann, René Nkoulou, Johannes M Schwenke, Dominique L Braun, Jacques Fellay, Philip E Tarr, for the Swiss HIV Cohort Study
doi : 10.1093/cid/ciac758
Clinical Infectious Diseases, Volume 76, Issue 1, 1 January 2023, Pages 48–56
In people with human immunodeficiency virus (HIV) (PWH), individual polygenic risk scores (PRSs) are associated with coronary artery disease (CAD) events. Whether PRSs are associated with subclinical CAD is unknown.
Pregnancy Status at the Time of Coronavirus Disease 2019 Vaccination and Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Maria C Magnus, Siri E Håberg, Ellen Ø Carlsen, Jeffrey C Kwong, Sarah A Buchan, Deshayne B Fell
doi : 10.1093/cid/ciac739
Clinical Infectious Diseases, Volume 76, Issue 1, 1 January 2023, Pages 57–65,
Pregnant women are recommended to receive coronavirus disease 2019 (COVID-19) vaccines; however, relative effectiveness of vaccination by pregnancy status is unclear.
Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial
Michael W Dunne, Steven I Aronin, Anita F Das, Karthik Akinapelli, Michael T Zelasky, Sailaja Puttagunta, Helen W Boucher
doi : 10.1093/cid/ciac738
Clinical Infectious Diseases, Volume 76, Issue 1, 1 January 2023, Pages 66–77
There are limited treatment options for uncomplicated urinary tract infection (uUTI) caused by resistant pathogens. Sulopenem etzadroxil/probenecid (sulopenem) is an oral thiopenem antibiotic active against multidrug-resistant pathogens that cause uUTIs.
Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial
Michael W Dunne, Steven I Aronin, Anita F Das, Karthik Akinapelli, Jeanne Breen, Michael T Zelasky, Sailaja Puttagunta
doi : 10.1093/cid/ciac704
Clinical Infectious Diseases, Volume 76, Issue 1, 1 January 2023, Pages 78–88
Sulopenem is a thiopenem antibiotic being developed for the treatment of multidrug-resistant infections. The availability of both intravenous (IV) and oral formulations will facilitate earlier hospital discharge.
Listeria monocytogenes Illness and Deaths Associated With Ongoing Contamination of a Multiregional Brand of Ice Cream Products, United States, 2010–2015
Amanda R Conrad, Sheri Tubach, Venessa Cantu, Lindsey Martin Webb, Steven Stroika, Steve Moris, Megan Davis, D Charles Hunt, Kristy K Bradley, Zuzana Kucerova, Errol Strain, Matthew Doyle, Angela Fields, Karen P Neil, L Hannah Gould, Kelly A Jackson, Matthew E Wise, Patricia M Griffin, Brendan R Jackson
doi : 10.1093/cid/ciac550
Clinical Infectious Diseases, Volume 76, Issue 1, 1 January 2023, Pages 89–95
Frozen foods have rarely been linked to Listeria monocytogenes illness. We describe an outbreak investigation prompted by both hospital clustering of illnesses and product testing.
Estimated Number of People Who Inject Drugs in the United States
Heather Bradley, Eric W Hall, Alice Asher, Nathan W Furukawa, Christopher M Jones, Jalissa Shealey, Kate Buchacz, Senad Handanagic, Nicole Crepaz, Eli S Rosenberg
doi : 10.1093/cid/ciac543
Clinical Infectious Diseases, Volume 76, Issue 1, 1 January 2023, Pages 96–102
Phage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease
Rebekah M Dedrick, Bailey E Smith, Madison Cristinziano, Krista G Freeman, Deborah Jacobs-Sera, Yvonne Belessis, A Whitney Brown, Keira A Cohen, Rebecca M Davidson, David van Duin, Andrew Gainey, Cristina Berastegui Garcia, C R Robert George, Ghady Haidar, Winnie Ip, Jonathan Iredell, Ameneh Khatami, Jessica S Little, Kirsi Malmivaara, Brendan J McMullan, David E Michalik, Andrea Moscatelli, Jerry A Nick, Maria G Tupayachi Ortiz, Hari M Polenakovik, Paul D Robinson, Mikael Skurnik, Daniel A Solomon, James Soothill, Helen Spencer, Peter Wark, Austen Worth, Robert T Schooley, Constance A Benson, Graham F Hatfull
doi : 10.1093/cid/ciac453
Clinical Infectious Diseases, Volume 76, Issue 1, 1 January 2023, Pages 103–112,
Nontuberculous Mycobacterium infections, particularly Mycobacterium abscessus, are increasingly common among patients with cystic fibrosis and chronic bronchiectatic lung diseases. Treatment is challenging due to intrinsic antibiotic resistance.
Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents in Israel
Ottavia Prunas, Daniel M Weinberger, Virginia E Pitzer, Sivan Gazit, Tal Patalon
doi : 10.1093/cid/ciac315
Clinical Infectious Diseases, Volume 76, Issue 1, 1 January 2023, Pages 113–118
The short-term effectiveness of a 2-dose regimen of the BioNTech/Pfizer BNT162b2 vaccine for adolescents has been demonstrated. However, little is known about the long-term effectiveness in this age group.
Genomic Insights Into the Mechanism of Carbapenem Resistance Dissemination in Enterobacterales From a Tertiary Public Heath Setting in South Asia
Refath Farzana, Lim S Jones, Md Anisur Rahman, Kirsty Sands, Andries J van Tonder, Edward Portal, Jose Munoz Criollo, Julian Parkhill, Martyn F Guest, W John Watkins, Monira Pervin, Ian Boostrom, Brekhna Hassan, Jordan Mathias, Md Abul Kalam, Timothy R Walsh
doi : 10.1093/cid/ciac287
Clinical Infectious Diseases, Volume 76, Issue 1, 1 January 2023, Pages 119–133
10.6% patients were CRE positive. Only 27% patients were prescribed at least 1 antibiotic to which infecting pathogen was susceptible. Burn and ICU admission and antibiotics exposures facilitate CRE acquisition. Escherichia coli ST167 was the dominant CRE clone.
Supporting the Art: Medication Adherence Patterns in Persons Prescribed Ingestible Sensor-enabled Oral Pre-Exposure Prophylaxis to Prevent Human Immunodeficiency Virus Infection
Sara H Browne, Florin Vaida, Anya Umlauf, Amanda J Tucker, Terrence F Blaschke, Constance A Benson
doi : 10.1093/cid/ciac280
Clinical Infectious Diseases, Volume 76, Issue 1, 1 January 2023, Pages 134–143
Timely, accurate adherence data may support oral pre-exposure prophylaxis (PrEP) success and inform prophylaxis choice. We evaluated a Food and Drug Administration (FDA)-approved digital health feedback system (DHFS) with ingestible-sensor-enabled (IS) tenofovir-disoproxil-fumarate plus emtricitabine (Truvada®) in persons starting oral PrEP.
Predictors of Time to Coronavirus Disease 2019 Infection in the National Basketball Association: A Retrospective Case-Control Study
Raphael E Cuomo, Zhuoran Li, Vidya Purushothaman, Chenna Basavapatna-Shankar, Matthew Nali, Tim K Mackey
doi : 10.1093/cid/ciac746
Clinical Infectious Diseases, Volume 76, Issue 1, 1 January 2023, Pages 144–147
A case-control study was conducted between 1 December 2021 and 31 January 2022 to identify factors, which increase risk for coronavirus disease 2019 (COVID-19) among athletes in the National Basketball Association (NBA). Behavioral factors and stadium attendance significantly decreased time to COVID-19 infection, but local COVID-19 rates were not associated in a multivariable model.
Dupilumab Use Is Associated With Protection From Coronavirus Disease 2019 Mortality: A Retrospective Analysis
Alexandra N Donlan, Indika Mallawaarachchi, Jennifer M Sasson, Robert Preissner, Johanna J Loomba, William A Petri, Jr.
doi : 10.1093/cid/ciac745
Clinical Infectious Diseases, Volume 76, Issue 1, 1 January 2023, Pages 148–151
We previously found that type 2 immunity promotes coronavirus disease 2019 (COVID-19) pathogenesis in a mouse model. To test relevance to human disease, we used electronic health record databases and determined that patients on dupilumab (anti-interleukin [IL]-4R monoclonal antibody that blocks IL-13 and IL-4 signaling) at the time of COVID-19 infection had lower mortality.
Severely Restricting Abortion Threatens Equitable Health Outcomes for People With Human Immunodeficiency Virus
Megan Hadley, Anna Powell
doi : 10.1093/cid/ciac721
Clinical Infectious Diseases, Volume 76, Issue 1, 1 January 2023, Pages 152–154
Equitable access to abortion is a critical component of reproductive care. Women with human immunodeficiency virus (HIV) in the United States are disproportionately Black and will be disproportionately affected by abortion bans following the Supreme Court's decision to overturn Roe v Wade.
Antivirals With Activity Against Mpox: A Clinically Oriented Review
Emily A Siegrist, Joseph Sassine
doi : 10.1093/cid/ciac622
Clinical Infectious Diseases, Volume 76, Issue 1, 1 January 2023, Pages 155–164
Mpox virus is an emergent human pathogen. While it is less lethal than smallpox, it can still cause significant morbidity and mortality.
Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs
Louis D Saravolatz, Shawn Depcinski, Mamta Sharma
doi : 10.1093/cid/ciac180
Clinical Infectious Diseases, Volume 76, Issue 1, 1 January 2023, Pages 165–171,
At a crucial time with rapid spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant globally, the United States Food and Drug Administration has issued an emergency use authorization for 2 oral antivirals, molnupiravir (in persons aged ≥18 years) and nirmatrelvir-ritonavir (Paxlovid) (in persons aged ≥12 years weighing ≥40 kg), for the outpatient treatment of patients with mild to moderate coronavirus disease 2019 (COVID–19) who are at risk for progression.
A Kidney Transplant Patient Suffering From Embolic Phenomenon
Alexis Guenette, Robin Chamberland, Henry Randall, Fadee Abu Al Rub
doi : 10.1093/cid/ciac002
Clinical Infectious Diseases, Volume 76, Issue 1, 1 January 2023, Pages 172–174
Correct Calculation of Confidence Interval for Proportion of Superior Comparisons Between Desirability of Outcome Ranking Scores
Mark R Loewenthal, Joshua S Davis, Michael Dymock
doi : 10.1093/cid/ciac348
Clinical Infectious Diseases, Volume 76, Issue 1, 1 January 2023, Pages 175–176
Response to Loewenthal et al
Scott Evans
doi : 10.1093/cid/ciac351
Clinical Infectious Diseases, Volume 76, Issue 1, 1 January 2023, Page 176
When Emulating a Trial, Do as the Trialists Do: Missteps in Estimating Relative Effectiveness of a Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Booster Dose
Kathleen E Wirth, Jessie K Edwards, Lydia Feinstein, Alexander Breskin
doi : 10.1093/cid/ciac700
Clinical Infectious Diseases, Volume 76, Issue 1, 1 January 2023, Pages 176–177
Reply to Wirth et al
Victor B Talisa, Florian B Mayr, Adeel A Butt
doi : 10.1093/cid/ciac701
Clinical Infectious Diseases, Volume 76, Issue 1, 1 January 2023, Pages 177–178
Phimosis as a Complication of Resolved Mpox
George R Thompson, III, Angel N Desai, Sonja M Neumeister, Anna M Arutyunova, Stuart H Cohen
doi : 10.1093/cid/ciac677
Clinical Infectious Diseases, Volume 76, Issue 1, 1 January 2023, Pages 178–179
Environmental Testing of Surfaces in the Room of a Patient With Mpox
Matthew P Muller, Sharmistha Mishra, Allison McGeer, Samir Patel, Jonathan Gubbay, Maan Hasso, Adrienne K Chan, Robert Kozak, Jerome A Leis, Darrell S Tan Author Notes
doi : 10.1093/cid/ciac654
Clinical Infectious Diseases, Volume 76, Issue 1, 1 January 2023, Pages 179–181
Correction to: Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR)
doi : 10.1093/cid/ciac352
Clinical Infectious Diseases, Volume 76, Issue 1, 1 January 2023, Page 182
Correction to: Impact of Point-of-Care Testing on the Management of Sexually Transmitted Infections in South Africa: Evidence from the HVTN702 Human Immunodeficiency Virus Vaccine Trial
doi : 10.1093/cid/ciac898
Clinical Infectious Diseases, Volume 76, Issue 1, 1 January 2023, Page 182
Correction to: Leveraging Serosurveillance and Postmortem Surveillance to Quantify the Impact of Coronavirus Disease 2019 in Africa
doi : 10.1093/cid/ciac897
Clinical Infectious Diseases, Volume 76, Issue 1, 1 January 2023, Page 183
Correction to: Risk Factors for Mortality Among Children Younger Than Age 5 Years With Severe Diarrhea in Low- and Middle-income Countries: Findings From the World Health Organization-coordinated Global Rotavirus and Pediatric Diarrhea Surveillance Networks
doi : 10.1093/cid/ciac865
Clinical Infectious Diseases, Volume 76, Issue 1, 1 January 2023, Page 183
